Indian Pharma to launch generic antiviral Covid-19 pill
Dr Reddy’s Laboratories Ltd, an Indian drug maker, will launch its generic version of Merck’s antiviral COVID-19 pill, molnupiravir, priced at $0.4693 per capsule, a company spokesperson said.
The overall cost for a patient treated with a 5-day course of 40 capsules of the generic drug, to be sold under brand name ‘Molflu’, will come up to $18.77. In comparison, the treatment with Merck’s pill in the United States costs $700.
“Molflu is expected to be available from early next week in pharmacies throughout (India) with particular focus on states with high caseload of COVID-19,” the company spokesperson from Dr Reddy’s said.
India last week gave emergency use approval to molnupiravir along with two vaccines, as the country braces for a possible spike in coronavirus cases due to the rapidly spreading Omicron variant. Molflu is expected to be available from early next week in pharmacies in India.
Related news
- China’s economy bolsters as it eases monetary policy, investment firm says · 6 Jan
- PrestigePEO and StaffLink Outsourcing LCC merger to expand clientele · 6 Jan
- Fujitsu partners with major tech firms to launch digital academy · 5 Jan
Disclosure: Outsource Accelerator uses AI tools in the backend of its editorial workflow. Every article is reviewed and verified by a human editor before publication.
Stay ahead of the outsourcing industry. Join thousands of business leaders who rely on Outsource Accelerator for the news, trends, and expert insights that matter. Subscribe to our free newsletter and never miss an update.
